April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Two-year Outcome of Half-time Reduced Fluence Photodynamic Therapy Combined with Intravitreal Ranibizumab for Retinal Angiomatous Proliferation
Author Affiliations & Notes
  • Akihiro Chiba
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Hirotaka Yokouchi
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Masayasu Kitahashi
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Mariko Kubota
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Takayuki Baba
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Shuichi Yamamoto
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Footnotes
    Commercial Relationships Akihiro Chiba, None; Hirotaka Yokouchi, None; Masayasu Kitahashi, None; Mariko Kubota, None; Takayuki Baba, None; Shuichi Yamamoto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4943. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akihiro Chiba, Hirotaka Yokouchi, Masayasu Kitahashi, Mariko Kubota, Takayuki Baba, Shuichi Yamamoto; Two-year Outcome of Half-time Reduced Fluence Photodynamic Therapy Combined with Intravitreal Ranibizumab for Retinal Angiomatous Proliferation. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4943.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study the efficacy of half-time reduced fluence photodynamic therapy (RF-PDT) combined with intravitreal ranibizumab (IVR) for retinal angiomatous proliferation (RAP).

Methods: Ten eyes of 10 patients with RAP were studied; 2 eyes with RAP stage II A, 4 eyes with RAP stage II B, and 4 eyes with RAP stage III. Combination therapy consisting of three monthly injections of IVR and a single half-time RF-PDT with verteporfin applied 1-3 days after the first ranibizumab injection. The dose and fluence of the half-time RF-PDT was administered according to the standard protocol for age-related macular degeneration (AMD). The laser treatment was given for 42 seconds guided by the indocyanine green (ICG) angiograms. The best-corrected visual acuity (BCVA) and central foveal thickness (CFT) determined by optical coherence tomography (OCT) were measured before and 24 months after the treatment.

Results: The BCVA was 0.90±0.44 logMAR units at the baseline and 0.74±0.43 logMAR units at 24 months after half-time RF-PDT. The BCVA improved at 24 months but the improvement was not significant (P=0.06). The BCVA improved by ≥0.15 logMAR units in 5 eyes (50%), remained stable in 3 eyes (30%), and worsened in 2 eyes (20%). The CFT was significantly reduced from 638.9±235.0 μm to 146.6±85.7 μm (P=0.005) at 24 months. The CFT decreased by ≥30% in 9 eyes (90%), remained stable in 1 eye (10%), and no eye was worsened. No any additional treatment was required in 5 eyes (50%), but additional treatment was required in 5 eyes (50%). A complete occlusion of the retinal-retinal anastomosis (RRA) was achieved and central macular edema (CME) disappeared in 9 eyes at 24 months. The mean number of RF-PDT treatments and IVR injections during the 24 month follow-up, including the treatments in the initial regimen, was 1.3 and 5.0, respectively. No complications such as severe vision loss, endophthalmitis, occlusion of the choriocapillaris, or systemic events developed.

Conclusions: Half-time RF-PDT combined with IVR for RAP effectively maintained or improved the BCVA and reduced the exudation in the long-term.

Keywords: 412 age-related macular degeneration  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×